ELASMOGEN START-UP JOURNEY
GBI Magazine recently spoke to Dr Caroline Barelle, CEO & Founder of Elasmogen, to talk about her Start-Up journey and how the Deepbridge Life Sciences EIS Scheme influenced it.
REQUEST E-APPLICATION FORM | 01244 746000 | Log in
Don’t invest unless you’re prepared to lose all your money.
These are high-risk investments and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more.
Investments in unquoted companies carry high risks and investors could lose all funds invested. No established market exists for the trading of shares in private companies, making it difficult to sell shares. The value of tax reliefs depend on personal circumstances and may be subject to change in the future. Investors are encouraged to take independent legal, tax and financial advice before considering an investment.
By clicking below, you confirm that you are an FCA authorised firm or individual and agree to be directed to our website, which is for FCA authorised firms and individuals only. Persons who do not meet this classification should leave this page.
If you are not a professional financial adviser, please contact the Deepbridge Investor Relations Team on 01244 746000 or by email at enquiries@deepbridgecapital.com.
GBI Magazine recently spoke to Dr Caroline Barelle, CEO & Founder of Elasmogen, to talk about her Start-Up journey and how the Deepbridge Life Sciences EIS Scheme influenced it.
Recently, GBI Magazine sat down with FluoretiQ Co-Founder & CEO, Neciah Dorh, to talk about his Start-Up journey and how the Deepbridge Life Sciences EIS Scheme influenced it.
GBI Magazine recently spoke to Sameer Kothari, Chief Executive Director of Zilico Ltd, to talk about his Start-Up journey and how the Deepbridge Life Sciences EIS Scheme influenced it.
Cardiff Health Tech Firm, Glucose Republic has now closed a £500,000 investment round from Deepbridge Capital and the Development Bank of Wales, to build a system focused on what impact food has by combining biology and software.
As of today (12th January 2022), we are happy to announce that the Deepbridge Capital Technology Growth EIS Fund has now deployed over £100m of capital.
We are pleased to announce the launch of our brand new Deepbridge Discovery Podcast.
Listen to Episode One of the Deepbridge Discovery Podcast with guest, Savvas Neophytou, Partner & Head of Life Sciences – Deepbridge Capital by clicking here.
We are delighted to announce that we are the headline sponsor for Northcote's Obsession 2022 gourmet food festival.
One of Deepbridge's award-winning, leading European Cloud Software Technology Growth EIS Companies, Sardina Systems, has announced the opening of a new subsidiary in Luxembourg.
Explaining the strategic importance of the new subsidiary office, Kenneth Tan, CEO of Sardina Systems commented:
Deepbridge has today (19 January 2022) announced that Pathfinder Medical, a portfolio company within the Deepbridge Life Sciences EIS fund has secured a further £8.5 million funding round, led by BGF and Parkwalk.
The Deepbridge Technology Growth EIS and Deepbridge Life Sciences EIS usually deploy funds on a monthly basis, with numerous deployments expected between now and the 5th April 2022.
Please note that deployment in the 2021/22 tax year is subject to the closing date of 29th March 2022 for receipt of fully completed applications and cleared funds.
One of the world's largest global wealth managers, UBS, has partnered with Fund Her North, working to improve access to finance for female-led businesses.
Fund Her North is made up of over 28 women in venture capital, including Samantha Piddington (Head of Corporate Finance - Deepbridge Capital), funding organisations and angel groups with a combined investment power of over £450m.
Aegiq, a University of Sheffield spin-out developing networking technology that's secure in the quantum computing age, has raised £1.8 million in seed funding for its quantum photonics platform.
Deepbridge Capital and angel investors provided funds alongside High-Tech Gründerfonds, bringing Aegiq's total funding to date to £3.5 million. Aegiq is also considering funds to join a second seed round of funding.
Deepbridge Capital has recently been featured in the first issue of GB Investments Magazine for 2022.
Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.
What are the key risks?
1. You could lose all the money you invest
2. You are unlikely to be protected if something goes wrong
3. You won’t get your money back quickly
4. Don’t put all your eggs in one basket
5. The value of your investment can be reduced
If you are interested in learning more about how to protect yourself, visit the FCA’s website here. [https://www.fca.org.uk/investsmart]